|
|
|
Piñana, José Luis; García Sanz, R.; Martino, Rodrigo; García Roa, María; Martín Martín, Gabriel Andrés; Risco Gálvez, Irene; Martino, Rodrigo; Tormo Díaz, Mar; Martínez Barranco, Pilar; Martínez Barranco, Pilar; Marcos Corrales, Sara; Calabuig, Marisa; Conesa, Venancio; Teruel, Anabel; Ruiz Pérez, Sara; Solano Vercet, Carlos; Navarro Ortega, David; Cedillo, Ángel; Sureda, Anna
|
|
This document is a artículoDate2022
|
|
Patients with hematological malignancies have been excluded from the new zoonotic coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) vaccine trials despite being at higher risk for SARS-CoV-2 disease (COVID-19)-related mortality. However, most health authorities worldwide have designated these patients as a priority for COVID-19 vaccination, even in the absence of efficacy data in these highly immunosuppressed patients. In addition, on 12 August 2021, the US Food and Drug Administration amended the emergency use authorizations for the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for the use of an additional dose in immunocompromised individuals, such as solid organ transplant recipients or equivalently immunosuppressed patients. |
|
Piñana, José Luis García Sanz, R. Martino, Rodrigo García Roa, María Martín Martín, Gabriel Andrés Risco Gálvez, Irene Martino, Rodrigo Tormo Díaz, Mar Martínez Barranco, Pilar Martínez Barranco, Pilar Marcos Corrales, Sara Calabuig, Marisa Conesa, Venancio Teruel, Anabel Ruiz Pérez, Sara Solano Vercet, Carlos Navarro Ortega, David Cedillo, Ángel Sureda, Anna 2022 Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19 Blood Advances 6 3 848 853 |
|
https://doi.org/10.1182/bloodadvances.2021006326
|